Cargando…

Cross-reactivity between cancer and microbial antigens

Detalles Bibliográficos
Autores principales:	Zitvogel, Laurence, Kroemer, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833730/ https://www.ncbi.nlm.nih.gov/pubmed/33537178 http://dx.doi.org/10.1080/2162402X.2021.1877416

Ejemplares similares

Prevention and treatment of cancers by tumor antigen-expressing Staphylococcus epidermidis
por: Kepp, Oliver, et al.
Publicado: (2023)

Immune infiltrate in cancer
por: Stoll, Gautier, et al.
Publicado: (2015)

Immunological effects of chemotherapy in spontaneous breast cancers
por: Kroemer, Guido, et al.
Publicado: (2013)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
por: Kepp, Oliver, et al.
Publicado: (2020)

Victories and deceptions in tumor immunology: Stimuvax(®)
por: Kroemer, Guido, et al.
Publicado: (2013)

Bile acids regulate MAdCAM-1 expression to link the gut microbiota to cancer immunosurveillance
por: Fidelle, Marine, et al.
Publicado: (2023)

Failure of immunosurveillance accelerates aging
por: Perez-Lanzon, Maria, et al.
Publicado: (2019)

COVID-19: a challenge for oncology services
por: Routy, Bertrand, et al.
Publicado: (2020)

Tumor-infiltrating lymphocytes for melanoma immunotherapy
por: Kepp, Oliver, et al.
Publicado: (2023)

Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling
por: Fidelle, Marine, et al.
Publicado: (2023)

Can the exome and the immunome converge on the design of efficient cancer vaccines?
por: Kroemer, Guido, et al.
Publicado: (2012)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

The intimate relationship between gut microbiota and cancer immunotherapy
por: Elkrief, Arielle, et al.
Publicado: (2018)

Impact of microbiota on breast cancer hormone therapy
por: Terrisse, Safae, et al.
Publicado: (2023)

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
por: Terrisse, Safae, et al.
Publicado: (2022)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy
por: Kroemer, Guido, et al.
Publicado: (2012)

CD4(+) T Cells at the Center of Inflammaging
por: Kroemer, Guido, et al.
Publicado: (2020)

Boosting the immunotherapy response by nutritional interventions
por: Zitvogel, Laurence, et al.
Publicado: (2022)

Trial watch: IDO inhibitors in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Trial watch: STING agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts
por: Stoll, Gautier, et al.
Publicado: (2018)

Cross-reactivity and sequence similarity between microbial transglutaminase and human tissue antigens
por: Lerner, Aaron, et al.
Publicado: (2023)

Trial watch: TLR3 agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Trial watch: dietary interventions for cancer therapy
por: Lévesque, Sarah, et al.
Publicado: (2019)

The European Academy of Tumor Immunology: Bridging fields, continents and generations
por: Kroemer, Guido, et al.
Publicado: (2012)

Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy
por: Ma, Yuting, et al.
Publicado: (2014)

Beneficial autoimmunity and maladaptive inflammation shape epidemiological links between cancer and immune-inflammatory diseases
por: Pol, Jonathan, et al.
Publicado: (2022)

Following up tumor-specific regulatory T cells in cancer patients
por: Zitvogel, Laurence, et al.
Publicado: (2013)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
por: Liu, Peng, et al.
Publicado: (2022)

TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves
por: Enot, David P., et al.
Publicado: (2018)

Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
por: Petrazzuolo, Adriana, et al.
Publicado: (2022)

Trial watch: Oncolytic viruses for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial watch: Monoclonal antibodies in cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Chemosensitization strategies for the treatment of lung cancer
por: Senovilla, Laura, et al.
Publicado: (2015)

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
por: Hirsch, Laure, et al.
Publicado: (2018)

Trial watch: Cardiac glycosides and cancer therapy
por: Menger, Laurie, et al.
Publicado: (2013)

Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy
por: Stoll, Gautier, et al.
Publicado: (2014)

Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies
por: Stoll, Gautier, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qc3on6bleop1d0knthg3snrhrt